BEIJING – Diabetes-focused Hua Medicine (Shanghai) Ltd. became the first drugmaker to reveal phase III data of a glucokinase activator (GKA) designed to treat type 2 diabetes. On June 18, it said its first-in-class GKA, dorzagliatin, showed sustained efficacy and safety for the 52-week treatment period with reductions in HbA1c levels in a completed phase III trial as a monotherapy.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aurinia, Azevan, Boehringer, Clover, Cohbar, Cyclerion, Cymabay, Finch, Genentech, Lilly, Nkamerica, Novartis, Novo, Otsuka, Reistone, Ridgeback, Sanofi, Uniqure.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Affiris, Aptinyx, Aribio, Eloxx, Genentech, Heat, Hua, Innovent, Lineage Cell, Pfizer, Sangamo, Seattle Genetics, Teva, Xeris.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affimed, Akero, Ascentage, Ascletis, Astrazeneca, Atara, Biomarin, Biosig, Cara, Contrafect, Dare, Dynavax, Evgen, Inflarx, Kiniksa, Lilly, Merck, Nantpharma, Recordati, Remegen, Sagimet.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affibody, Amylyx, Applied Therapeutics, Ardelyx, Atyr, Bayer, Beyondspring, Cardiff Oncology, Catalyst, Genentech, Glycomimetics, Humanigen, Immunic, Immunicum, Inventiva, Iveric, Kyowa Kirin, Lilly, Lundbeck, Momenta, Navidea, Oncimmune, Phathom, PTC, Roche, Sinovac, Solasia, Tarsus.

HONG KONG – Astellas Pharma Inc. reported positive results from phase III of its DOLOMITES study comparing the efficacy and safety of roxadustat to that of darbepoetin alfa in treating anemia in nondialysis-dependent, stage 3 to 5 chronic kidney disease (CKD) patients.